![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NOVARTIS, NEXMED SIGN NAIL FUNGUS LICENSING DEAL
NOVARTIS, NEXMED SIGN NAIL FUNGUS LICENSING DEAL
September 15, 2005
Novartis AG said it has signed a global licensing agreement with NexMed Inc to develop new topical forms of terbinafine, the active ingredient in its Lamisil treatment for fungal nail infections. Novartis has acquired the exclusive rights to further develop and commercialize NexMed's NM100060 nail lacquer treatment for onychomycosis, which is commonly known as nail fungus, and for any other indications, according to a statement. NM100060 is currently in Phase I development with the active ingredient terbinafine.
Forbes (http://www.forbes.com/home/feeds/afx/2005/09/15/afx2225549.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct